HPV 16 and its role in the development of cervical cancer: prevention, diagnosis and treatment

Human papillomavirus type 16 (HPV 16) is the most oncogenic and one of the most common genotypes of human papillomavirus. Its oncogenic properties make it play a key role in the development of many cancers, including cervical, throat, anal and other malignant tumors. The main route of HPV infection is sexual contact. This article characterizes the HPV 16 virus and its unique oncogenic properties. The epidemiology of infections and preventive strategies, including vaccinations and screening programs, which have significantly reduced the number of cases of HPV-related cancers, are discussed. Modern diagnostic methods, such as genetic tests and cytology, which enable early detection of infections and precancerous lesions, are also presented. The article also addresses the issues of treatment of lesions caused by HPV 16, including local therapies used in the case of precancerous lesions and comprehensive methods of treating advanced cancers. The last part discusses research perspectives, such as the development of new vaccines and immunotherapy, which may play a key role in the fight against this virus in the future. This article highlights the importance of an interdisciplinary approach to the prevention, diagnosis, and treatment of HPV 16 infections, which is essential to reducing the global burden of cancers associated with this virus.